Eduardo Santos da Silva, Marina Borges Rabelo de Santana, Elisânia Fontes Silveira, Rogério Tanan Torres, Raphael Chagas Silva, Antônio Márcio Santana Fernandes, Emília Maria Medeiros de Andrade Belitardo, Luis Fabián Salazar Garcés, Leonardo Freire Santiago, Juan Ricardo Urrego, Deise Souza Vilas-Bôas, Luiz Antônio Rodrigues de Freitas, Josefina Zakzuk, Luis Gustavo Carvalho Pacheco, Álvaro Augusto Cruz, Fatima Ferreira, Philip Cooper, Luis Caraballo, Carina da Silva Pinheiro, Neuza Maria Alcantara-Neves
BACKGROUND: Allergen-specific immunotherapy (AIT) is the only disease-modifying treatment approach to change disease-causing allergens. Hypoallergenic derivatives show promise as potential therapeutics, amongst which BTH2 was designed to induce tolerance against Blomia tropicalis allergy. Our aim was to investigate the hypoallergenicity and immunoregulatory activity of BTH2 in vitro and its therapeutic potential in a mouse model of AIT. METHODS: Recombinant Blo t 5 and Blo t 21 allergens and their hybrid derivatives (BTH1 and BTH2) were expressed and purified...
February 13, 2023: Clinical and Experimental Allergy